Telix Pharmaceuticals Ltd (STU:T3X)
€ 14.8 0.49 (3.42%) Market Cap: 4.90 Bil Enterprise Value: 4.84 Bil PE Ratio: 162.08 PB Ratio: 19.98 GF Score: 75/100

Half Year 2022 Telix Pharmaceuticals Ltd Earnings Call Transcript

Aug 17, 2022 / 11:00PM GMT
Operator

Thank you for standing by, and welcome to the Telix Pharmaceuticals Limited First Half 2022 Financial Results Presentation. (Operator Instructions)

I would now like to hand the conference over to Kyahn Williamson, Senior Vice President of Investor Relations and Corporate Communications. Please go ahead.

Kyahn Williamson
Telix Pharmaceuticals Limited - SVP of Corporate Communications & IR

Good morning. Thank you, Harmony. And thank you, everybody, for joining us today. It's my pleasure -- as mentioned, my name is Kyahn Williamson. I'm Senior Vice President, Investor Relations and Corporate Communication at Telix, and it's my pleasure to introduce my colleagues who are also presenting on today's call in order: Dr. Christian Behrenbruch, our Group CEO and Managing Director; Darren Smith, our Group Chief Financial Officer; and Dr. Colin Hayward, our Group Chief Medical Officer.

Just move to the next slide, please. So the -- our financial results were lodged this morning on the ASX, you'll see those documents there. For those joining by phone

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot